Next 10 |
home / stock / glpg / glpg articles
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymph...
Bank of America Securities downgrades European drugmaker Galapagos NV (NASDAQ:GLPG) to underperform, citing few catalysts in the near term. Gal...
Publication of annual report for financial year 2023 Annual Shareholders' Meeting resolutions include approval of revised Remuneration Polic...
Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current f...
- First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRASG12C Cancers - FMC-376 is a first-in-class direct dual inhibitor of ON+OFF ...
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 C...
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the successful completion of the tra...
Thermo Fisher Scientific to provide CAR-T manufacturing and kitting services for Galapagos' point-of-care CAR-T product candidate in the San...
On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: ...
News, Short Squeeze, Breakout and More Instantly...
2024-04-21 21:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymph...
Bank of America Securities downgrades European drugmaker Galapagos NV (NASDAQ:GLPG) to underperform, citing few catalysts in the near term. Gal...